IL276322B2 - Lipid-like nanocomplexes and their uses - Google Patents

Lipid-like nanocomplexes and their uses

Info

Publication number
IL276322B2
IL276322B2 IL276322A IL27632220A IL276322B2 IL 276322 B2 IL276322 B2 IL 276322B2 IL 276322 A IL276322 A IL 276322A IL 27632220 A IL27632220 A IL 27632220A IL 276322 B2 IL276322 B2 IL 276322B2
Authority
IL
Israel
Prior art keywords
compound
alkyl
independently
heteroaryl
aryl
Prior art date
Application number
IL276322A
Other languages
Hebrew (he)
Other versions
IL276322A (en
IL276322B1 (en
Original Assignee
Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College filed Critical Tufts College
Publication of IL276322A publication Critical patent/IL276322A/en
Publication of IL276322B1 publication Critical patent/IL276322B1/en
Publication of IL276322B2 publication Critical patent/IL276322B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)

Claims (15)

276322/ WHAT IS CLAIMED IS:
1. A compound of formula (I): (I), wherein A, a hydrophilic head, is , in which each of Ra, Ra’, Ra”, and Ra”’, independently, is H, C1-C20 alkyl, C2-Calkenyl, C2-C20 alkynyl, C3-C20 cycloalkyl, C1-C20 heteroalkyl, C1-Cheterocycloalkyl, aryl, or heteroaryl; and Z is a C1-C20 bivalent aliphatic radical, a C1-C20 bivalent heteroaliphatic radical, a bivalent aryl radical, or a bivalent heteroaryl radical; B is C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, C3-C24 cycloalkyl, C1-C24 heteroalkyl, C1-C24 heterocycloalkyl, aryl, or heteroaryl, or ; each of R1 and R2 is a C1-C20 bivalent aliphatic radical; each of R3 and R4, independently, is H or C1-C10 alkyl, or R3 and R4, together with the atom to which they are attached, form C3-C10 cycloalkyl; R5 is C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, C3-C24 cycloalkyl, C1-C24 heteroalkyl, C1-C24 heterocycloalkyl, aryl, or heteroaryl; W is O, S, or Se; V is a bond, O, S, or Se; X, a linker, is 276322/4 or , in which each of L1, L3, and L4, independently, is a bond, O, S, or NRc; L2 is O, S, or NRc; G is O, S, or NRd; Q is ORf, SRg, or NRhRi; and each of r and t, independently, is 1-6, each of Rc, Rd, Rf, Rg, Rh, and Ri, independently, being H, C1-C10 alkyl, C1-Cheteroalkyl, aryl, or heteroaryl; and m is 0 or 1, provided that m is 1 when V is S.
2. The compound of claim 1, wherein A is or .
3. The compound of claim 1 or 2, wherein B is .
4. The compound of any one of claims 1-3, wherein X is , , , , , or , each of Rc and Rd, independently, being H or C1-C10 alkyl.
5. The compound of any one of claims 1-4, wherein each of R1 and R2 is a C1-C4 bivalent aliphatic radical; each of R3 and R4, independently, is H or C1-C4 alkyl; and R5 is C1-C20 alkyl.
6. The compound of any one of claims 1-5, wherein W is O, S, or Se; and V is a bond.
7. The compound of any one of claims 1-5, wherein each of W and V, independently, is O or Se, and m is 0. 276322/4
8. The compound of any one of claims 1-5, wherein each of W and V is O or S; and m is 1.
9. The compound of any one of claims 1-8, wherein A is an amino moiety formed from one of the following amines: , , , , , , , , , , , , , , , , , and .
10. The compound of any one of claims 1-8, wherein A is an amino moiety formed from one of the following amines: , , , , , , , , , , , , , , , , 276322/4 , , , , , , , , , , , , , , , , , , , , , , 276322/4 , , , , , , , , , , , , , , , 276322/4 , , , , , , or .
11. The compound of any one of claims 1-10, wherein A is or ; B is ; 276322/4 each of R1 and R2 is a C1-C4 bivalent aliphatic radical; each of R3 and R4, independently, is H or C1-C4 alkyl; and R5 is C1-C20 alkyl.
12. The compound of any one of claims 1-11, wherein A is an amino moiety formed from one of the following amines: , , , , , , and .
13. A pharmaceutical composition comprising a nanocomplex, the nanocomplex is formed of a compound of any one of claims 1-12, and a protein; wherein the nanocomplex has a particle size of 50 nm to 1000 nm, and the compound binds to the protein via a non-covalent interaction, a covalent bond, or both.
14. The pharmaceutical composition of claim 13, wherein the protein is GFP-Cre or CRISPR/Cas9.
15. A pharmaceutical composition of claim 13 or 14 for use in treating of a medical condition.
IL276322A 2018-02-01 2019-02-01 Lipid-like nanocomplexes and their uses IL276322B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862625153P 2018-02-01 2018-02-01
PCT/US2019/016362 WO2019152848A1 (en) 2018-02-01 2019-02-01 Lipid-like nanocomplexes and uses thereof

Publications (3)

Publication Number Publication Date
IL276322A IL276322A (en) 2020-09-30
IL276322B1 IL276322B1 (en) 2024-08-01
IL276322B2 true IL276322B2 (en) 2024-12-01

Family

ID=67478550

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276322A IL276322B2 (en) 2018-02-01 2019-02-01 Lipid-like nanocomplexes and their uses

Country Status (11)

Country Link
US (2) US12133855B2 (en)
EP (1) EP3746129A4 (en)
JP (2) JP7497045B2 (en)
KR (1) KR102904334B1 (en)
CN (1) CN111954542A (en)
AU (1) AU2019215157B2 (en)
BR (1) BR112020015796A2 (en)
CA (1) CA3089826A1 (en)
IL (1) IL276322B2 (en)
MX (1) MX2020007944A (en)
WO (1) WO2019152848A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
WO2019152848A1 (en) 2018-02-01 2019-08-08 Trustees Of Tufts College Lipid-like nanocomplexes and uses thereof
JP2023504568A (en) 2019-12-04 2023-02-03 オルナ セラピューティクス インコーポレイテッド Circular RNA compositions and methods
US20230097743A1 (en) * 2020-03-02 2023-03-30 Trustees Of Tufts College Imidazole-based synthetic lipidoids for in vivo mrna delivery into immune cells
JP2023518295A (en) 2020-03-20 2023-04-28 オルナ セラピューティクス インコーポレイテッド Circular RNA compositions and methods
BR112022022358A2 (en) * 2020-05-04 2023-01-31 Tufts College MATERIALS LIKE SYNTHETIC LIPIDS FOR BRAIN DELIVERY
CN116018142A (en) * 2020-06-12 2023-04-25 塔夫茨大学信托人 pH-responsive lipidoid nanoparticles for intracellular mRNA delivery
DK4182297T3 (en) 2020-07-16 2025-12-01 Acuitas Therapeutics Inc CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES
JP2023552555A (en) * 2020-12-07 2023-12-18 トラスティーズ オブ タフツ カレッジ Lipidoid compositions and methods of use thereof
AU2022208484A1 (en) * 2021-01-15 2023-08-24 The Brigham And Women's Hospital, Inc. Lipid nanoparticles for targeted delivery of mrna
CN113402404B (en) 2021-04-30 2022-03-11 苏州科锐迈德生物医药科技有限公司 Lipid compound, lipid carrier containing same, nucleic acid lipid nanoparticle composition and pharmaceutical preparation
CN113387825A (en) * 2021-06-10 2021-09-14 福州大学 Long-chain alkyl ester amine compound or fluorine-containing long-chain alkyl ester amine compound and kilogram-level preparation method thereof
IL308746A (en) 2021-06-10 2024-03-01 Orna Therapeutics Inc Circular rna compositions and methods
CA3233243A1 (en) 2021-09-30 2023-04-06 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
TW202334080A (en) 2021-11-08 2023-09-01 美商歐納醫療公司 Lipid nanoparticle compositions for delivering circular polynucleotides
CN114163345B (en) * 2021-12-15 2022-07-26 武汉滨会生物科技股份有限公司 Ionizable lipid compound and nucleic acid in-vitro cell transfection reagent
CN114191561B (en) * 2021-12-15 2022-08-02 武汉滨会生物科技股份有限公司 Application of ionizable lipid compound in nucleic acid drug delivery system
KR20240122872A (en) * 2021-12-16 2024-08-13 아퀴타스 테라퓨틱스 인크. Fluorinated cationic lipids for use in lipid nanoparticles
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CN116813493A (en) * 2022-03-21 2023-09-29 苏州科锐迈德生物医药科技有限公司 A lipid compound and lipid carrier based on it, nucleic acid lipid nanoparticle composition and pharmaceutical preparation
CN114716355B (en) * 2022-04-02 2023-09-05 华南理工大学 Lipid compound, composition containing lipid compound and application of lipid compound
CN114773217B (en) 2022-06-20 2022-10-18 深圳市瑞吉生物科技有限公司 Cationic lipid compounds and compositions for delivery of nucleic acids and uses
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
WO2024077232A2 (en) * 2022-10-07 2024-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods for t cell targeted delivery of therapeutic agents and activation of t cells
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
TW202425959A (en) 2022-11-08 2024-07-01 美商歐納醫療公司 Lipids and nanoparticle compositions for delivering polynucleotides
CN116063245B (en) * 2022-12-05 2024-09-10 南开大学 MRNA liposome nano particle with degradable center and preparation method and application thereof
KR102758330B1 (en) * 2023-02-22 2025-01-23 주식회사 서지넥스 Ionizable lipid comprising sulfide and lipid nanoparticle comprising thereof
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
KR102902665B1 (en) * 2024-11-29 2025-12-22 이화여자대학교 산학협력단 Biodegradable Ionizable Lipids Incorporating Ethylene Glycol and Lipid Nanoparticles for Drug Delivery using the same
CN119320334A (en) * 2024-12-19 2025-01-17 国家纳米科学中心 Ionizable lipid compound with three-dimensional space structure, preparation method and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE682393C (en) * 1933-04-14 1939-10-13 I G Farbenindustrie Akt Ges Process for the production of quaternary nitrogen compounds
US4275236A (en) * 1979-12-26 1981-06-23 Sherex Chemical Company, Inc. Tertiary di-(β-hydroxy organo) amine oxides and their preparation
WO1997019675A2 (en) * 1995-11-30 1997-06-05 Vical Incorporated Complex cationic lipids
US5994317A (en) * 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins
JP4087637B2 (en) * 2001-04-23 2008-05-21 信越化学工業株式会社 Novel tertiary amine compound having ester structure and process for producing the same
FR2873376B1 (en) * 2004-07-23 2006-11-24 Tetrahedron Sas NOVEL SELENO-HYDROXYACIDS AND DERIVATIVES, NUTRITION APPLICATIONS, COSMETICS AND PHARMACY
CA2841881A1 (en) 2011-07-12 2013-01-17 General Electric Company Polymer and method for removing undesirable elements from aqueous solutions
CN103131227B (en) 2013-02-23 2015-05-13 北京化工大学 Preparation method of biofouling-resistant coating
ES2859923T3 (en) * 2013-02-28 2021-10-04 Univ Tufts Disulfide compounds for the supply of pharmaceutical agents
WO2014186366A1 (en) * 2013-05-13 2014-11-20 Tufts University Nanocomplexes for delivery of saporin
US10888622B2 (en) 2013-05-14 2021-01-12 Trustees Of Tufts College Nanocomplexes of modified peptides or proteins
WO2014210356A1 (en) 2013-06-26 2014-12-31 Massachusetts Institute Of Technology Multi-tailed lipids and uses thereof
JP6558369B2 (en) 2014-07-17 2019-08-14 凸版印刷株式会社 Thermal transfer image-receiving sheet and method for producing the same
US10457631B2 (en) 2016-04-06 2019-10-29 Ohio State Innovation Foundation Biodegradable amino-ester nanomaterials for nucleic acid delivery
WO2017212006A1 (en) * 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
EP3490611A4 (en) 2016-07-26 2020-04-15 Trustees Of Tufts College ANTIBODY CONJUGATED NANOPARTICLES AND THEIR MEDICAL USES
WO2019152848A1 (en) 2018-02-01 2019-08-08 Trustees Of Tufts College Lipid-like nanocomplexes and uses thereof

Also Published As

Publication number Publication date
US12133855B2 (en) 2024-11-05
US20230405022A1 (en) 2023-12-21
JP2021512865A (en) 2021-05-20
AU2019215157A1 (en) 2020-08-13
WO2019152848A1 (en) 2019-08-08
KR20200115591A (en) 2020-10-07
JP2024116162A (en) 2024-08-27
BR112020015796A2 (en) 2021-02-09
EP3746129A1 (en) 2020-12-09
US20200368254A1 (en) 2020-11-26
KR102904334B1 (en) 2025-12-24
IL276322A (en) 2020-09-30
JP7497045B2 (en) 2024-06-10
EP3746129A4 (en) 2022-03-02
CN111954542A (en) 2020-11-17
AU2019215157B2 (en) 2024-12-19
MX2020007944A (en) 2020-11-24
IL276322B1 (en) 2024-08-01
JP7650112B2 (en) 2025-03-24
CA3089826A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
IL276322B2 (en) Lipid-like nanocomplexes and their uses
JP2018528261A5 (en)
JP2016153410A5 (en)
JP2008522981A5 (en)
BR112014014599A8 (en) alpha-aminoamidine polymers and their use
EP4410317A3 (en) Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
CY1122792T1 (en) MONO-OR DISUBTITUTED INDOLE DERIVATIVES AS DANGE VIRUS REPLICATION INHIBITORS
WO2020113213A3 (en) Cyclic pantetheine derivatives and uses thereof
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
CA3057882A1 (en) Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
AR065404A1 (en) PHARMACO-BINDING CONJUGATES, THOSE WHO JOIN POWERFUL CYTOTOXINS, PHARMACEUTICAL COMPOSITION THAT CONTAIN THEM AND THEIR USE TO DELAY OR STOP THE GROWTH OF A TUMOR IN A MAMMER
MX379581B (en) AMINOALCOHOL LIPIDOIDS AND THEIR USES.
WO2016134301A3 (en) Neuroactive steroids, compositions, and uses thereof
EA201992082A1 (en) HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR
CN1878757A (en) Pyridone derivatives and their applications
RU2021103727A (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COMBATING CARDIOTOXICITY CAUSED BY CHEMOTHERAPY
JP2018531941A5 (en)
JP2016506916A5 (en)
JP2017533930A5 (en)
CY1112084T1 (en) 5-phenylthiazole derivative and its use as kinase inhibitors PI3
JP2016521256A5 (en)
BR112018068278A2 (en) 3-deoxy derivative and its pharmaceutical compositions
JP2013172743A5 (en)
EA201791872A1 (en) POLYCYCLIC CARBAMOILPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATIONS